Concepedia

Publication | Open Access

Phase II study of E7070 in patients with metastatic melanoma

DOIFull Paper Access

59

Citations

7

References

2004

Year

J F Smyth, S. Aamdal, Ahmad Awada, Christian Dittrich, Francesco Caponigro, Patrick Schöffski, Martin Gore, Thierry Lesimple, N. Djurasinovic, B. Barón,
Annals of Oncology

References

YearCitations

Quantitative Chemical Proteomics for Identifying Candidate Drug Targets

Yoshiya Oda, Takashi Owa, Toshitaka Sato,

Analytical Chemistry

2003

190

E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo

Yoichi Ozawa, Naoko Hata Sugi, Takeshi Nagasu,

European Journal of Cancer

2001

132

Mechanisms of Action of the Novel Sulfonamide Anticancer Agent E7070 on Cell Cycle Progression in Human Non-Small Cell Lung Cancer Cells

Kazuya Fukuoka, Jitsuo Usuda, Yasuo Iwamoto,

Investigational New Drugs

2001

113

Phase I and Pharmacokinetic Study of E7070, a Novel Chloroindolyl Sulfonamide Cell-Cycle Inhibitor, Administered as a One-Hour Infusion Every Three Weeks in Patients With Advanced Cancer

Éric Raymond, W.W. ten Bokkel Huinink, Jos H. Beijnen,

Journal of Clinical Oncology

2002

64

Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)

Cornelis J. A. Punt, P. Fumoleau, Baudouin van de Walle,

Annals of Oncology

2001

60

Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.

動物学雑誌

1900

53

Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)

C. Terret, Sylvie Zanetta, Henri Roché,

European Journal of Cancer

2003

50

Page 1